CARDIFF ONCOLOGY, INC. Sale of Stock, Consideration Received on Transaction
CARDIFF ONCOLOGY, INC. (CRDF) reported Sale of Stock, Consideration Received on Transaction of $34.19 million for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-02.
Discontinued › Notes › Equity
us-gaap:SaleOfStockConsiderationReceivedOnTransaction · last filed 2023-03-02
- CARDIFF ONCOLOGY, INC. sale of stock, consideration received on transaction for the quarter ending 2020-06-30 was $17.28M.
- CARDIFF ONCOLOGY, INC. sale of stock, consideration received on transaction for fiscal 2021 was $34.19M, a 69.56% decline from fiscal 2020.
- CARDIFF ONCOLOGY, INC. sale of stock, consideration received on transaction for fiscal 2020 was $112.30M.
| Period end | Sale of Stock, Consideration Received on Transaction | Sale of Stock, Consideration Received on Transaction 3 month | Sale of Stock, Consideration Received on Transaction 3 month as first filed | Sale of Stock, Consideration Received on Transaction 12 month | Sale of Stock, Consideration Received on Transaction 12 month as first filed |
|---|---|---|---|---|---|
| 2021-12-31 | $34.19M 10-K · filed 2023-03-02 | ||||
| 2020-12-31 | $112.30M 10-K · filed 2022-02-24 | $112.30M 10-K · filed 2021-02-25 | |||
| 2020-10-02 | $94.00M 10-K · filed 2022-02-24 | ||||
| 2020-06-30 | $17.28M 10-Q · filed 2021-11-04 | $17.28M 10-Q · filed 2020-08-11 | |||
| 2020-05-26 | $2.50M 10-Q · filed 2020-11-05 | ||||
| 2020-05-14 | $810.00K 10-Q · filed 2020-11-05 | ||||
| 2020-04-09 | $1.10M 10-Q · filed 2020-11-05 | ||||
| 2020-03-30 | $1.00M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |